This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Michael Parr, PhD
Director of Formulation and Process Development at Evonik

Profile

Dr. Parr’s professional expertise includes drug delivery systems, formulation, viral vector design, GLP and GMP activities and clinical development. Dr. Parr holds a Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia and completed post-doctoral studies at Harvard Medical School. He currently serves as part of the Evonik Health Care division, in the position of Director of Formulation and Process Development for the Vancouver site, responsible for leading multifunctional teams and ensuring the successful execution of a portfolio of complex customer-funded development programs as part of the Parenteral Drug Delivery Solutions business.

Agenda Sessions

  • Considerations for Scaling Lipid Based Parenteral Nanomedicines

    14:00